Long-Term Outcomes of Anticoagulation for Bioprosthetic Valve Thrombosis

Petrescu, Ioana; Egbe, Alexander C.; Ionescu, Filip; Nkomo, Vuyisile T.; Greason, Kevin L.; Pislaru, Cristina; Pellikka, Patricia A.; Connolly, Heidi M.; Pislaru, Sorin

doi:10.1016/j.jacc.2019.12.037

Cited by 43 publications

(25 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Anticoagulation using a VKA and/or UFH is the first-line treatment of BHV thrombosis. Because BHV thrombosis is associated with recurrence and early prosthetic degeneration, indefinite anticoagulation should be considered after a confirmed episode, but this strategy must be balanced against an increased risk of bleeding 544,545 (Figure 10).…”

Section: Valve Thrombosismentioning

confidence: 99%

2021 ESC/EACTS Guidelines for the management of valvular heart disease

Vahanian¹,

Beyersdorf²,

Praz³

et al. 2022

EuroIntervention

570

581

View full text Add to dashboard Cite

The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their dating. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of health care or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies. However, the ESC Guidelines do not override in any way whatsoever the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with that patient and the patient's caregiver where appropriate and/or necessary. Nor do the ESC Guidelines exempt health professionals from taking careful and full consideration of the relevant official updated recommendations or guidelines issued by the competent public health authorities in order to manage each patient's case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional's responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.

show abstract

Section: Valve Thrombosismentioning

confidence: 99%

2021 ESC/EACTS Guidelines for the management of valvular heart disease

Vahanian¹,

Beyersdorf²,

Praz³

et al. 2022

EuroIntervention

570

581

View full text Add to dashboard Cite

show abstract

“…Additionally, BPVT recurred in 23% of warfarin responders after a median of 23 months, and all but one patient with recurrent BPVT responded to anticoagulation. Thus, longer term or even indefinite anticoagulation with warfarin could be considered after an initial BPVT episode while balancing bleeding risks 8 . In retrospect, we believe that our patient's presentation of BPV stenosis two years prior to the current presentation was likely BPVT.…”

Section: Discussionmentioning

confidence: 80%

“…Early diagnosis of BPVT is crucial as most patients respond to anticoagulation and BPVT resolves completely, thus avoiding need for repeat valvular intervention. Several studies have reported successful resolution of BPVT when treated with VKA (vitamin K antagonist) 5‐8 . A prospective evaluation of warfarin showed that anticoagulation was effective in 83% of patients with suspected BPVT, and most responded within 3 months 7 .…”

Section: Discussionmentioning

confidence: 99%

Recurrent bioprosthetic mitral valve thrombosis treated with anticoagulation

2020

View full text Add to dashboard Cite

show abstract

“…The topic of bioprosthetic valve thrombosis in SAVR was addressed in a series of 100 patients from the Mayo Clinic. 44 The authors demonstrate that the presence of bioprosthetic valve thrombosis appears to affect long-term durability even though initial anticoagulation treatment may be successful. Patients with valve thrombosis and thrombotic events had worse long-term outcome compared with patients without valve thrombosis, despite successful anticoagulation treatment.…”

Section: Classic Aortic Valve Surgerymentioning

confidence: 96%

Cardiac Surgery 2020 Reviewed

Doenst

Caldonazo

Schneider

et al. 2021

Thorac Cardiovasc Surg

View full text Add to dashboard Cite

In 2020, nearly 30,000 published references appeared in the PubMed for the search term “cardiac surgery.” While SARS-CoV-2 affected the number of surgical procedures, it did not affect outcomes reporting. Using the PRISMA approach, we selected relevant publications and prepared a results-oriented summary. We reviewed primarily the fields of coronary and conventional valve surgery and their overlap with interventional alternatives. The coronary field started with a discussion on trial data value and their interpretation. Registry comparisons of coronary artery bypass surgery (CABG) and percutaneous coronary intervention confirmed outcomes for severe coronary artery disease and advanced comorbidities with CABG. Multiple arterial grafting was best. In aortic valve surgery, meta-analyses of randomized trials report that transcatheter aortic valve implantation may provide a short-term advantage but long-term survival may be better with classic aortic valve replacement (AVR). Minimally invasive AVR and decellularized homografts emerged as hopeful techniques. In mitral and tricuspid valve surgery, excellent perioperative and long-term outcomes were presented for structural mitral regurgitation. For both, coronary and valve surgery, outcomes are strongly dependent on surgeon expertise. Kidney disease increases perioperative risk, but does not limit the surgical treatment effect. Finally, a cursory look is thrown on aortic, transplant, and assist-device surgery with a glimpse into the current stand of xenotransplantation. As in recent years, this article summarizes publications perceived as important by us. It does not expect to be complete and cannot be free of individual interpretation. We aimed to provide up-to-date information for decision-making and patient information.

show abstract

Long-Term Outcomes of Anticoagulation for Bioprosthetic Valve Thrombosis

Cited by 43 publications

References 17 publications

2021 ESC/EACTS Guidelines for the management of valvular heart disease

2021 ESC/EACTS Guidelines for the management of valvular heart disease

Recurrent bioprosthetic mitral valve thrombosis treated with anticoagulation

Cardiac Surgery 2020 Reviewed

Contact Info

Product

Resources

About